RE:RE:RE:RE:RE:RE:My questions and a response from FredI had absolutely also heard that at least one of the 4050 analogues was performing substantially better than 4050 in pre clinical...for very specific indications. The big takeaway and corporate intention in all of this.. given there is apparently a meaningful patentable difference in efficacy by indication...is the ability to outright sell the worldwide rights of one or more of the analogues, and continue to forward the others.
For instance, it would not surprise me at all if Prometic surprised everyone and sold 4050 worldwide rights for something like IPF.... and then used what should be VERY substantial proceeds to pursue CKD and other major analogue potential indications. I candidly would love to see a bold deal
like that, monetizing IP and virtually guaranteeing a very bright future for the company